Company profile
Perspective Therapeutics, Inc.
AMEX:CATXBiotechnology: Pharmaceutical Preparations
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06710756 | phase1_2 | recruiting | 2025-04-28 | 2028-01-31 | Perspective Therapeutics | Lead-212 PSV359 Therapy for Patients With Solid Tumors |
| NCT05655312 | phase1_2 | recruiting | 2023-06-01 | 2027-12-31 | Perspective Therapeutics | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma |
| NCT05636618 | phase1_2 | recruiting | 2023-09-27 | 2029-11-26 | Perspective Therapeutics | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors |
| NCT04904120 | phase1 | completed | 2021-03-05 | 2022-09-20 | Perspective Therapeutics | Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy |
FDA applications (0)
No records yet.